Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

GD(2)-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD(2) antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebert, Nikolai, Troschke-Meurer, Sascha, Marx, Madlen, Zumpe, Maxi, Ehlert, Karoline, Gray, Juliet, Garaventa, Alberto, Manzitti, Carla, Ash, Shifra, Klingebiel, Thomas, Beck, James, Castel, Victoria, Valteau-Couanet, Dominique, Loibner, Hans, Ladenstein, Ruth, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210332/
https://www.ncbi.nlm.nih.gov/pubmed/30336605
http://dx.doi.org/10.3390/cancers10100387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210332/
https://www.ncbi.nlm.nih.gov/pubmed/30336605
http://dx.doi.org/10.3390/cancers10100387

Ejemplares similares